• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌症免疫治疗中 CAR T 细胞制造的潜在解决方案。

Potential solutions for manufacture of CAR T cells in cancer immunotherapy.

机构信息

Fraunhofer Institute for Cell Therapy and Immunology (IZI), Leipzig, Germany.

Fraunhofer Cluster of Excellence for Immune-Mediated Disease, Frankfurt, Germany.

出版信息

Nat Commun. 2022 Sep 5;13(1):5225. doi: 10.1038/s41467-022-32866-0.

DOI:10.1038/s41467-022-32866-0
PMID:36064867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9445013/
Abstract

CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.

摘要

嵌合抗原受体 T 细胞疗法是一种有效的癌症治疗方法，但生物和制造方面的障碍阻碍了其广泛突破。虽然已经朝着 CAR 细胞的自动化制造迈出了第一步，但仍需要新技术来实现对大量患者群体的治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63c6/9445013/470adf3055e0/41467_2022_32866_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63c6/9445013/8d31518e4739/41467_2022_32866_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63c6/9445013/470adf3055e0/41467_2022_32866_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63c6/9445013/8d31518e4739/41467_2022_32866_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63c6/9445013/470adf3055e0/41467_2022_32866_Fig2_HTML.jpg

相似文献

1
Potential solutions for manufacture of CAR T cells in cancer immunotherapy.癌症免疫治疗中 CAR T 细胞制造的潜在解决方案。
Nat Commun. 2022 Sep 5;13(1):5225. doi: 10.1038/s41467-022-32866-0.
2
Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.嵌合抗原受体 T 细胞疗法治疗癌症：以基础研究为导向的观点。
Immunotherapy. 2018 Mar;10(3):221-234. doi: 10.2217/imt-2017-0133.
3
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.先天和类先天细胞：嵌合抗原受体 (CAR) 细胞治疗的未来。
Trends Pharmacol Sci. 2021 Jan;42(1):45-59. doi: 10.1016/j.tips.2020.11.004. Epub 2020 Nov 26.
4
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.免疫细胞改造：创造更智能嵌合抗原受体 T 细胞的挑战和临床方法。
Front Immunol. 2018 Jul 31;9:1717. doi: 10.3389/fimmu.2018.01717. eCollection 2018.
5
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.下一代嵌合抗原受体 T 细胞：克服毒性的安全策略。
Mol Cancer. 2019 Aug 20;18(1):125. doi: 10.1186/s12943-019-1057-4.
6
Next Steps in the CAR Journey of a Thousand Miles.千里CAR征程的下一步。
Mol Ther. 2017 Oct 4;25(10):2226-2227. doi: 10.1016/j.ymthe.2017.09.013. Epub 2017 Sep 20.
7
Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.实体瘤和年龄相关病症中的衰老细胞裂解性嵌合抗原受体T细胞
Mol Ther. 2020 Oct 7;28(10):2108-2110. doi: 10.1016/j.ymthe.2020.08.011. Epub 2020 Aug 25.
8
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.嵌合抗原受体 T 细胞免疫疗法治疗实体瘤的展望。
Front Immunol. 2018 May 22;9:1104. doi: 10.3389/fimmu.2018.01104. eCollection 2018.
9
Advances in off-the-shelf CAR T-cell therapy.现成的嵌合抗原受体T细胞疗法的进展。
Clin Adv Hematol Oncol. 2019 Mar;17(3):155-157.
10
Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.阻断 T 细胞中 CD38 驱动的自相残杀可增强 CD38 特异性嵌合抗原受体 T 细胞的抗肿瘤活性。
J Genet Genomics. 2019 Aug 20;46(8):367-377. doi: 10.1016/j.jgg.2019.06.007. Epub 2019 Aug 13.

引用本文的文献

1
Next-generation T cell immunotherapies engineered with CRISPR base and prime editing: challenges and opportunities.采用CRISPR碱基编辑和引导编辑技术设计的下一代T细胞免疫疗法：挑战与机遇
Nat Rev Clin Oncol. 2025 Sep 19. doi: 10.1038/s41571-025-01072-4.
2
CAR-T cell therapy for glioblastoma: advances, challenges, and future directions.胶质母细胞瘤的嵌合抗原受体T细胞疗法：进展、挑战与未来方向
Ann Med Surg (Lond). 2025 Jul 18;87(9):5743-5756. doi: 10.1097/MS9.0000000000003607. eCollection 2025 Sep.
3
The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping.

本文引用的文献

1
Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL.嵌合抗原受体 T 细胞输注产品的单细胞抗原特异性全景分析确定了 ALL 患者 CD19 阳性复发的决定因素。
Sci Adv. 2022 Jun 10;8(23):eabj2820. doi: 10.1126/sciadv.abj2820. Epub 2022 Jun 8.
2
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?嵌合抗原受体T细胞作为大B细胞淋巴瘤的二线治疗：是一种范式转变吗？
Blood. 2022 May 5;139(18):2737-2746. doi: 10.1182/blood.2022015789.
3
Rapid manufacturing of non-activated potent CAR T cells.
基因治疗时代：慢病毒载体及其假型化的进展
Viruses. 2025 Jul 24;17(8):1036. doi: 10.3390/v17081036.
4
Design of soluble Notch agonists that drive T cell development and boost immunity.驱动T细胞发育并增强免疫力的可溶性Notch激动剂的设计。
Cell. 2025 Jul 29. doi: 10.1016/j.cell.2025.07.009.
5
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies.工程化过继性细胞免疫疗法中生物医学虚拟孪生体的设计规范。
NPJ Digit Med. 2025 Aug 1;8(1):493. doi: 10.1038/s41746-025-01809-6.
6
Engineering Innate Immunity: Recent Advances and Future Directions for CAR-NK and CAR-Macrophage Therapies in Solid Tumors.工程化先天免疫：实体瘤中CAR-NK和CAR-巨噬细胞疗法的最新进展与未来方向
Cancers (Basel). 2025 Jul 19;17(14):2397. doi: 10.3390/cancers17142397.
7
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.肿瘤免疫治疗学会愿景：有机会更深入了解抗肿瘤活性、毒性和耐药性机制，以优化癌症免疫治疗。
J Immunother Cancer. 2025 Jun 25;13(6):e011929. doi: 10.1136/jitc-2025-011929.
8
Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium.嵌合抗原受体T细胞（CAR-T）学术生产质量控制测试的协调统一：UNITC联盟生物生产工作小组的立场文件
Bone Marrow Transplant. 2025 May 29. doi: 10.1038/s41409-025-02637-8.
9
Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes.细胞轨迹调控：CAR-T细胞功能表型的快速微流控生物物理分析
Nat Commun. 2025 May 22;16(1):4775. doi: 10.1038/s41467-025-59789-w.
10
An Analysis of Monitoring Solutions for CAR T Cell Production.嵌合抗原受体T细胞（CAR T细胞）生产监测解决方案分析
Healthc Technol Lett. 2025 May 13;12(1):e70012. doi: 10.1049/htl2.70012. eCollection 2025 Jan-Dec.
快速制造非激活型有效 CAR T 细胞。
Nat Biomed Eng. 2022 Feb;6(2):118-128. doi: 10.1038/s41551-021-00842-6. Epub 2022 Feb 21.
4
Decade-long leukaemia remissions with persistence of CD4 CAR T cells.长达十年的白血病缓解期与 CD4 CAR T 细胞的持续存在。
Nature. 2022 Feb;602(7897):503-509. doi: 10.1038/s41586-021-04390-6. Epub 2022 Feb 2.
5
Engineering enhanced CAR T-cells for improved cancer therapy.工程改造增强型嵌合抗原受体T细胞以改善癌症治疗。
Nat Cancer. 2021 Aug;2(8):780-793. doi: 10.1038/s43018-021-00241-5. Epub 2021 Aug 19.
6
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.T记忆干细胞的克隆性扩增决定了患者早期的抗白血病反应以及嵌合抗原受体T细胞（CAR T细胞）的长期持久性。
Nat Cancer. 2021 Jun;2(6):629-642. doi: 10.1038/s43018-021-00207-7. Epub 2021 May 24.
7
The clinical pipeline for cancer cell therapies.癌细胞疗法的临床研发进程。
Nat Rev Drug Discov. 2021 Jul;20(7):503-504. doi: 10.1038/d41573-021-00100-z.
8
Recent advances and discoveries in the mechanisms and functions of CAR T cells.嵌合抗原受体 T 细胞的作用机制及功能的最新进展和发现。
Nat Rev Cancer. 2021 Mar;21(3):145-161. doi: 10.1038/s41568-020-00323-z. Epub 2021 Jan 22.
9
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.基因编辑的、供体来源的同种异体抗 CD19 嵌合抗原受体 T 细胞治疗儿童和成人 B 细胞急性淋巴细胞白血病：两项 1 期研究结果。
Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5.
10
Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.肿瘤负荷、炎症和产品属性决定了阿基仑赛注射液治疗大B细胞淋巴瘤的疗效。
Blood Adv. 2020 Oct 13;4(19):4898-4911. doi: 10.1182/bloodadvances.2020002394.